1. Home
  2. URGN vs NGL Comparison

URGN vs NGL Comparison

Compare URGN & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$19.99

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Logo NGL ENERGY PARTNERS LP

NGL

NGL ENERGY PARTNERS LP

HOLD

Current Price

$11.90

Market Cap

751.7M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
NGL
Founded
2004
1940
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Natural Gas Distribution
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
751.7M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
URGN
NGL
Price
$19.99
$11.90
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$29.50
N/A
AVG Volume (30 Days)
728.3K
459.1K
Earning Date
03-09-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$96,516,000.00
$3,250,313,000.00
Revenue This Year
$26.47
N/A
Revenue Next Year
$110.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.00
46.95
52 Week Low
$3.42
$2.64
52 Week High
$30.00
$12.34

Technical Indicators

Market Signals
Indicator
URGN
NGL
Relative Strength Index (RSI) 44.27 68.05
Support Level $18.97 $10.11
Resistance Level $22.07 $9.99
Average True Range (ATR) 1.31 0.50
MACD 0.06 0.19
Stochastic Oscillator 49.24 65.22

Price Performance

Historical Comparison
URGN
NGL

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About NGL NGL ENERGY PARTNERS LP

NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.

Share on Social Networks: